Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Robert Leeth

Nurse Practitioner, Psychiatric/Mental Health Coeur D Alene, ID Nurse Practitioner

NPI 1881657237 CMS profile 10805572

909 W Canfield Ave, Coeur D Alene, ID 83815

Open in the dashboard

General payments

$4,321

156 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Leeth of Coeur D Alene, ID is reported in the CMS Open Payments database as having received $4,321 across 156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,002 88
2024 General $806 40
2023 General $139 9
2022 General $349 17
2021 General $25 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Leeth
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Robert Leeth were reported at $3,002. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Robert Leeth Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $25 $166 $54–$482 $132
2022 $349 $195 $66–$559 $149
2023 $139 $233 $82–$673 $160
2024 $806 $236 $84–$688 $164
2025 $3,002 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neuronetics, Inc. $1,126 3 payments
  2. ITI, Inc. $821 44 payments
  3. Janssen Pharmaceuticals, Inc $372 8 payments
  4. Otsuka America Pharmaceutical, Inc. $359 18 payments
  5. Teva Pharmaceuticals USA, Inc. $318 13 payments
  6. Lundbeck LLC $201 11 payments
  7. Alkermes, Inc. $198 10 payments
  8. Axsome Therapeutics, Inc. $165 11 payments
  9. AbbVie, Inc. $160 8 payments
  10. Sunovion Pharmaceuticals Inc. $111 7 payments
  11. Other $489 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,479 152 payments
  2. Travel and Lodging $783 2 payments
  3. Education $59 2 payments
Products named General payments · program years 2021–2025
  1. Neurostar TMS Therapy System $1,126 3 payments
  2. CAPLYTA Psychiatry $489 26 payments
  3. INVEGA SUSTENNA $372 8 payments
  4. CAPLYTA Psychiatry $332 18 payments
  5. REXULTI Psychiatry $237 15 payments
  6. REXULTI Psychiatry $201 11 payments
  7. LYBALVI Cns $198 10 payments
  8. UZEDY $161 7 payments
  9. Austedo XR $157 6 payments
  10. LYBALVI Cns $136 7 payments
  11. Other $1,815 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

178

Median for Nurse Practitioner: 389

Drug cost

$48,968

Median for Nurse Practitioner: $21,885

Branded share of claims

21.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 13 $43,005
Aripiprazole Generic 16 $2,221
Vilazodone Hcl Generic 15 $1,370
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $753
Methylphenidate Hcl Generic 20 $562
Duloxetine Hcl Generic 15 $370
Water Water For Irrigation,sterile Brand 11 $246
Trazodone Hcl Generic 35 $220
Zaleplon Generic 12 $141
Metoprolol Succinate Generic 11 $54

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $155
$155 — —
LYBALVI
  • Alkermes, Inc. $62
$62 — —
Azstarys
  • Corium, Inc. $62
$62 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $59
$59 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record